Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

AIMS/INTRODUCTION: The sodium–glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post‐hoc analysis to evaluate the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Takashi, Mori‐Anai, Kazumi, Kawaguchi, Yutaka, Katsumata, Hideyuki, Tsuda, Hidetaka, Iida, Mitsutaka, Arakawa, Kenji, Jardine, Meg J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756319/
https://www.ncbi.nlm.nih.gov/pubmed/34212533
http://dx.doi.org/10.1111/jdi.13624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756319/
https://www.ncbi.nlm.nih.gov/pubmed/34212533
http://dx.doi.org/10.1111/jdi.13624

Ejemplares similares